CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Grant or award EVP of R&D acquired 148,035 shares (grant or award)
- 4 Grant or award Director acquired 1,282,976 shares (grant or award)
- 4 Grant or award President and CEO acquired 1,924,464 shares (grant or award)
- 4 Shares withheld for taxes President and CEO gave up 22,340 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 35,879 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Technical Officer gave up 8,351 shares (to pay taxes)
- 4 Shares withheld for taxes General Counsel gave up 23,628 shares (to pay taxes)
- 4 Open-market sale General Counsel sold 3,000 shares at $6.85 ($20,550)
- 4 Grant or award EVP of R&D acquired 251,908 shares (grant or award)
- 4 Open-market sale General Counsel sold 3,000 shares at $7.04 ($21,120)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale General Counsel sold 5,602 shares at $7.53 ($42,186)
- 4 Shares withheld for taxes EVP of R&D gave up 8,464 shares (to pay taxes)
- 4 Shares withheld for taxes EVP of R&D gave up 8,968 shares (to pay taxes)
- 4 Open-market sale Director sold 15,000 shares at an average $16.75 ($251,250)
- 4 Open-market sale Director sold 15,000 shares at an average $16.75 ($251,250)
- 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.97 ($23,940)
- 4 Grant or award Director acquired 35,328 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale EVP of R&D and CMO sold 2,000 shares at $11.44 ($22,880)
Page 6 of 14 · 275 filings